Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Following Complete or Partial Response to Platinum Based Chemotherapy”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Not applicableApproved For MarketingNCT03079687
What this trial is testing

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Who this might be right for
Ovarian Cancer
AstraZeneca
Large-scale testing (Phase 3)Active Not RecruitingNCT01874353
What this trial is testing

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Who this might be right for
Platinum SensitiveBRCA MutatedRelapsed Ovarian Cancer+1 more
AstraZeneca 327
Testing effectiveness (Phase 2)WithdrawnNCT00408967
What this trial is testing

Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.

Who this might be right for
Ovarian Cancer
EMD Serono
Post-approval studies (Phase 4)Not Yet RecruitingNCT06887933
What this trial is testing

A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
GlaxoSmithKline 67
Post-approval studies (Phase 4)Study completedNCT02476968
What this trial is testing

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer

Who this might be right for
BRCA or HRR+ Mutated Ovarian Cancer Patients
AstraZeneca 181
Large-scale testing (Phase 3)WithdrawnNCT02392676
What this trial is testing

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Who this might be right for
Platinum Sensitive Relapsed Ovarian Cancer
AstraZeneca
Large-scale testing (Phase 3)Study completedNCT03534453
What this trial is testing

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Who this might be right for
Relapsed Ovarian CancerFollowing Complete or Partial Response to Platinum Based ChemotherapyPlatinum Sensitive
AstraZeneca 229